Long-term Renal Effects of Proton Pump Inhibitor Use

Affiliations

¹ Department of Nephrology, Austin Health, Melbourne, Australia.
² Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Comment

Benjamin Lazarus et al. Gastroenterology. 2020 Mar.

. 2020 Mar;158(4):1173-1174.

doi: 10.1053/j.gastro.2019.07.066. Epub 2019 Dec 10.

¹ Department of Nephrology, Austin Health, Melbourne, Australia.
² Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

No abstract available

Comment in

Reply.
Moayyedi P, Eikelboom J, Yusuf S. Moayyedi P, et al. Gastroenterology. 2020 Mar;158(4):1175-1176. doi: 10.1053/j.gastro.2019.12.023. Epub 2020 Jan 7. Gastroenterology. 2020. PMID: 31917257 No abstract available.

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S; COMPASS Investigators. Moayyedi P, et al. Gastroenterology. 2019 Sep;157(3):682-691.e2. doi: 10.1053/j.gastro.2019.05.056. Epub 2019 May 29. Gastroenterology. 2019. PMID: 31152740 Clinical Trial.